Design of an in-dwelling cannula for convection-enhanced delivery

Failures of recent convection-enhanced delivery (CED) trials have underscored the need for improved CED cannulae. This study presents a novel in-dwelling cannula targeted for use in upcoming neuro-oncological or neurodegeneration trials. The cannula is reflux-resistant and easily integrated into clinical workflows. The cannula was evaluated in non-human primate CED studies performed with magnetic resonance imaging (MRI) to validate the effectiveness and safety of the infusion.

[1]  Krystof S. Bankiewicz,et al.  Real-time MR imaging of adeno-associated viral vector delivery to the primate brain , 2009, NeuroImage.

[2]  Takeshi Kimura,et al.  Transcatheter closure of patent ductus arteriosus with the Inoue single-branched stent graft. , 2005, The Journal of thoracic and cardiovascular surgery.

[3]  M. Berger,et al.  Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates , 2011, NeuroImage.

[4]  A. Vortmeyer,et al.  Local distribution and toxicity of prolonged hippocampal infusion of muscimol. , 2005, Journal of neurosurgery.

[5]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P F Morrison,et al.  Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.

[7]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[8]  Yi Ai,et al.  Point source concentration of GDNF may explain failure of phase II clinical trial , 2006, Experimental Neurology.

[9]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Raghu Raghavan,et al.  Poor drug distribution as a possible explanation for the results of the PRECISE trial. , 2010, Journal of neurosurgery.

[11]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[12]  G. Gerhardt,et al.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.

[13]  M. Berger,et al.  Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.

[14]  P F Morrison,et al.  Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[15]  Ryuta Saito,et al.  Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. , 2005, Journal of neurosurgery.

[16]  M. Fiandaca,et al.  Image-guided convection-enhanced delivery platform in the treatment of neurological diseases , 2011, Neurotherapeutics.

[17]  William Jagust,et al.  Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.

[18]  E. Huang,et al.  Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[19]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.